Price (delayed)
$1.22
Market cap
$46.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.34
Enterprise value
$42.61M
We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple
There are no recent dividends present for FBLG.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.